Company news
Aytu BioPharma, Inc. news in 2022
Aytu BioPharma, Inc.'s news releases, calls and decks from 2022, newest first.
Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT(R) Prescriptions Generated Since Inception of RxConnect
November 29, 2022
Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso
November 15, 2022
Aytu BioPharma Reports Record Quarterly Revenue and Positive Adjusted EBITDA in First Quarter of Fiscal Year 2023
November 13, 2022
Aytu BioPharma to Report First Quarter Fiscal 2023 Financial Results on November 14, 2022
November 6, 2022
Aytu BioPharma Announces Agreement with Avenue Venture Debt Fund to Extend Interest-Only Period of Company's Term Loan
October 24, 2022
Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations and Indefinite Suspension of Clinical Development Programs
October 12, 2022
Aytu BioPharma Announces Continuing Availability of ADHD Medication Adzenys XR-ODT(R) in Response to Reported Generic Adderall(R) XR Supply Disruptions
October 4, 2022
Aytu BioPharma Reports Record Fourth Quarter and Fiscal Year 2022 Revenue
September 26, 2022
Aytu BioPharma Announces Addition of Fourth Patent License for AR101/Enzastaurin
September 13, 2022
Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin
August 15, 2022
Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering
August 14, 2022
Aytu BioPharma Announces Pricing of Public Offering
August 8, 2022
Aytu BioPharma Announces Launch of Public Offering
August 7, 2022
Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome
July 19, 2022
Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors
June 28, 2022
Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities
May 15, 2022
Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight(TM) Delivery Technology
April 24, 2022
Aytu BioPharma Announces Fast Track Designation Granted to AR101 for the Treatment of Vascular Ehlers-Danlos Syndrome
April 18, 2022
Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT(R)
March 22, 2022
Aytu BioPharma Announces Closing of $7.6 Million Registered Offering
March 6, 2022
Aytu BioPharma Announces Pricing of $7.6 Million Registered Offering
March 1, 2022
Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome
March 1, 2022
Aytu BioPharma Announces Business and Pipeline Progress and Reports Second Quarter 2022 Financial Results
February 13, 2022
Aytu BioPharma Completes $15 Million Debt Refinancing
January 30, 2022
Aytu BioPharma Appoints Mark Oki as Chief Financial Officer
January 3, 2022